



**HAL**  
open science

## **Extra Corporeal Life Support for Cardiac ARrest patients with post-cardiac arrest syndrome: the ECCAR study**

Adrien Bouglé, Arthur Le Gall, Florence Dumas, Guillaume Geri, Isabelle Malissin, Sebastian Voicu, Bruno Mégarbane, Alain Cariou, Nicolas Deye

### **► To cite this version:**

Adrien Bouglé, Arthur Le Gall, Florence Dumas, Guillaume Geri, Isabelle Malissin, et al.. Extra Corporeal Life Support for Cardiac ARrest patients with post-cardiac arrest syndrome: the ECCAR study. Archives of cardiovascular diseases, In press. hal-01942222

**HAL Id: hal-01942222**

**<https://hal.science/hal-01942222v1>**

Submitted on 3 Dec 2018

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 Extra Corporeal Life Support for Cardiac ARrest patients with post-cardiac arrest syndrome: the  
2 ECCAR study

3

4 Running Head: ECLS for Post Cardiac Arrest Syndrome

5

6 Adrien Bouglé<sup>\*1,4</sup>, MD ; Arthur Le Gall<sup>\*1,4</sup>, MD ; Florence Dumas<sup>2,4,6</sup>, MD, PhD ; Guillaume  
7 Geri<sup>1,4,6</sup>, MD, PhD ; Isabelle Malissin<sup>3,5</sup>, MD ; Sebastian Voicu<sup>3,5</sup>, MD ; Bruno Mégarbane<sup>3,5</sup>,  
8 MD, PhD ; Alain Cariou<sup>1,4,6</sup>, MD, PhD ; Nicolas Deye<sup>3,5</sup>, MD

9 \* A.B. and A.L.G have equally contributed to this work

10 <sup>1</sup> *Medical Intensive Care Unit, Cochin University Hospital, Assistance Publique – Hôpitaux de*  
11 *Paris, Paris, France;*

12 <sup>2</sup> *Emergency Department, Cochin University Hospital, Assistance Publique – Hôpitaux de*  
13 *Paris, Paris, France*

14 <sup>3</sup> *Medical and Toxicologic Intensive Care Unit, Lariboisière University Hospital, Assistance*  
15 *Publique – Hôpitaux de Paris, Paris, France*

16 <sup>4</sup> *Paris V University, Paris, France*

17 <sup>5</sup> *Paris VII University, Paris, France*

18 <sup>6</sup> *INSERM UMR-S970, Paris Cardiovascular Research Center, Paris, France*

## 19 **Conflict of interests**

20 No conflicts of interests to be declare

## 21 **Funding Source**

22 No external funding has been hired for this study. No conflicts of interest to declare.

23

24

25

26 **Word Count:** 4438 words

27

1 **Corresponding author:**

2 Adrien Bouglé, MD

3 Department of Anesthesiology and Critical Care Medicine, University Hospital La Pitié –  
4 Salpêtrière, Assistance Publique – Hopitaux de Paris, 47-83 Boulevard de l'Hôpital, 75013  
5 Paris, France

6 Mail: [adrien.bougle@aphp.fr](mailto:adrien.bougle@aphp.fr)

7 Tel: +33 1 42 16 29 91

8 Fax: +33 1 42 16 39 79

9

1 **ABSTRACT**

2 Purpose: Post-Cardiac Arrest Shock (PCAS) occurring after resuscitated cardiac arrest (CA),  
3 is a main cause of early death. Extra-Corporeal Life Support (ECLS) could be useful pending  
4 recovery of myocardial failure. We aimed to describe our PCAS population, and factors  
5 associated with ECLS initiation.

6 Materials and Methods: This analysis included 924 patients admitted in two intensive care  
7 units (ICU) between 2005 and 2014 for CA and PCAS, and, of those patients, 43 patients for  
8 whom an ECLS was initiated. Neurological and ECLS-related outcomes were gathered  
9 retrospectively.

10 Results: The 43 ECLS patients were predominantly young males with evidence of myocardial  
11 infarction on coronary angiography (70%). ECLS was initiated in patients suffering from  
12 severe cardiovascular dysfunction (Left Ventricular Ejection Fraction: 15 [10 - 25] %), with a  
13 median delay of 9 [6 - 16] hours following CA. At one year, 8 patients survived (19%) without  
14 neurological disability. Blood lactate and coronary etiology were associated with neurological  
15 outcomes. Logistic regression conducted using 878 PCAS controls identified age, sex,  
16 current smoking, location of CA, blood lactate and creatinine levels as risk factors for  
17 initiation of ECLS.

18 Conclusions: ECLS, as a salvage therapy for PCAS, could represent an acceptable  
19 alternative for highly selected patients.

20

21

## 1 **Introduction**

2 Despite many improvements in Cardiac Arrest (CA) management, survival rate ranges from  
3 11 to 17% [1,2]. Among CA patients who survived initial resuscitation, less than 30%  
4 survived to hospital discharge [3–5]. Post Cardiac Arrest shock (PCAS), defined as the  
5 association of a myocardial dysfunction and vasoplegia occurring after return on  
6 spontaneous circulation (ROSC) [6], is globally responsible of one-third of deaths [5]. While  
7 persistence of myocardial dysfunction at 24h may be associated with early death [7], no  
8 differences in neurological outcomes have been shown between post-CA patients with PCAS  
9 and those without PCAS [5,7].

10 Recently, two studies have described the use of Extracorporeal Life Support (ECLS) in  
11 successfully resuscitated CA patients experiencing severe PCAS [8,9]. Although survival  
12 benefit was not demonstrated, ECLS-assisted patients had acceptable neurological  
13 prognosis. A solid understanding of key governing factors that lead those patients to die are  
14 thus requested to better select the patients the most likely to benefit for this strategy.

15 Our objectives were 1/ to describe a cohort of PCAS patients treated with ECLS and 2/ to  
16 identify factors that lead physicians to indicate initiation of ECLS in post-CA patients.

17

## 18 **Material and Methods**

### 19 *Population and Data collection:*

20 This retrospective observational study was conducted in two tertiary university centers in  
21 Paris. We included consecutive patients admitted to intensive care unit (ICU) for CA and  
22 PCAS (defined as the need for continuous norepinephrine or epinephrine infusion to maintain  
23 mean arterial pressure above 60 mmHg for more than 6 hours following restoration of ROSC  
24 despite adequate fluid loading [5]), and for whom an ECLS was initiated. Patients with

1 refractory CA and in-hospital CA (except those that occurred in the cath-lab and the  
2 emergency ward) were not included.

3 ECLS-treated patients' data were collected retrospectively. Prospective database  
4 implemented in Cochin Hospital was used to identify control group of patients experiencing  
5 PCAS without ECLS [2].

6 Our local ethics committees approved the data collection and study protocol (CE SRLF N°  
7 12-384).

### 8 *Treatment protocol*

9 Patients admitted for CA were treated according to international guidelines, and similar  
10 procedures have been described elsewhere [2,10]. ECLS implantation and patient's  
11 management during ECLS support, including anticoagulant treatment or weaning procedure  
12 followed ELSO guidelines [12] and were previously described [11].

13 Neurological outcome was daily assessed by ICU physicians, until death or ICU discharge.  
14 According to guidelines [13–16], neuroprognostication was performed daily using a  
15 multimodal approach, and life-sustaining therapies withdrawal decision was taken during a  
16 collegial consultation.

### 17 *Outcomes*

18 The primary outcome was the neurological evolution at one year, assessed by the Cerebral  
19 Performance Category [17] (Favorable Outcome : CPC score = I - II ; Poor Outcome: CPC  
20 score = III - V) [18] at 1 year.

### 21 *Analysis*

22 We performed a description of factors associated with unfavorable neurologic outcomes at  
23 one year in the population of PCAS patients treated with ECLS. A logistic regression was  
24 performed to assess the association between the selected variables and the neurological

1 outcome. ECLS group was compared with control group, using two-sided t test, or chi 2 test  
2 when necessary. Finally, we performed a univariate and multivariate analysis, using a  
3 stepwise logistic regression, to identify factors associated with the ECLS implantation.

4 Results are expressed as median (interquartiles 25-75) or number (percentage). The R  
5 project software (The R Foundation for Statistical Computing, Vienna, Austria) was used for  
6 statistical analysis.

7

## 8 **Results**

9 From January 2005 to December 2014, 46 PCAS patients treated by ECLS were included.  
10 Three patients were non-included because of in-Hospital CA. Among the 3 patients non-  
11 included, one was admitted for septic shock consecutive to a pulmonary infection, the CA  
12 occurred 8 days after the admission, and the patient deceased. One patient was a severely  
13 burned patient with ARDS. He deceased 17 days after his admission while on ECLS for CA  
14 consecutive to pulmonary embolism occurring 14 days after his admission. The last non-  
15 included patient was admitted for intoxication with beta-blockers, the ECLS being inserted 5  
16 days after his admission, for extreme hemodynamic instability, he died while on ECLS.

17 Finally, 43 patients fulfilled the inclusion criteria. We also include a control population  
18 composed by 878 PCAS patients. ECLS population was predominantly young males, with a  
19 previous history of coronary events (Table 1). Sixty percent of them presented an initial  
20 shockable rhythm, with No-Flow of 2 [0-10] min and a Low-Flow of 28 [14-42] min.  
21 Hemodynamic parameters are described in table 2.

22 Nine patients survived (21%) at ICU discharge: myocardial recovery was observed for 7  
23 patients (78%), one benefited from a heart transplantation, and one patient died at one year  
24 from end stage cancer. A favorable neurological outcome at one year was observed for 8  
25 (19%) of the ECLS cohort (89% of survivors).

1 Death rate during the ICU stay (79%) was mainly related to multiple organ failure (MOF)  
2 (63%). Forty-five percent of death by MOF occurred in the first three days after ICU  
3 admission (Figure 1). ECLS inefficacy, defined as the inability to maintain cardiac output and  
4 arterial pressure despite maximal therapeutic investment, was observed in 11 of deceased  
5 patients (31%). Life-sustaining therapy withdrawal was initiated for 9 of them (26%), and  
6 cerebral brain death was pronounced for 2 patients (6%).

7 No statistical difference was found between centers except for the percentage of bystander  
8 CPR and Low-Flow duration (Table S1).

9 ECLS-treated patients who survived without severe neurological disability were younger than  
10 those with severe neurological impairment (Table 1). CPR characteristics and severity scores  
11 were not different between the favorable and the poor neurological outcome group, despite  
12 OHCA score showed a trend toward higher values in poor neurological group. By contrast,  
13 blood lactate level at ECLS implantation discriminated the two groups (Table 2 and figure  
14 S1). Coronary etiology of CA was associated with unfavorable outcome at one year, whereas  
15 the arrhythmia was associated with a better prognosis (Table 1).

16 ECLS-treated patients were younger, with a longer time to ROSC and a higher proportion of  
17 non-public location of CA and bystander CPR, as compared to control group (Table 3).  
18 ECLS-treated patients had higher blood lactate and creatinine levels than the control.

19 In multivariate analysis (Figure 2), factors independently associated with ECLS implantation  
20 were as follows: age < 62 years old, serum creatinine > 109  $\mu\text{mol/l}$ , administration of  
21 adrenaline < 2 mg, and public location of CA.

22 When considering the whole PCAS population, non-survivors at ICU discharge were older  
23 and experienced higher blood lactate and serum creatinine levels (Table 4). Time to ROSC  
24 were longer when comparing non-survivors to survivors. The etiology for CA in survivors was  
25 predominantly cardiac, with higher rates of coronary angioplasty. The proportion of ECLS-  
26 treated patients was not different in survivors versus non-survivors.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

**Conclusions Discussion**

~~Emphasizing on functional neurological outcomes, this observational study offers interesting findings.~~

The present retrospective study aimed at reporting the ten-year experience of two Parisian intensive care units in the application of ECLS for PCAS patients. Even though the death rate was high, the survivors of ECLS-treated PCAS population exerted no or minor neurological disabilities. Furthermore, the death rate in the ECLS-treated population is of a magnitude of the death rate of the PCAS population, although the severity was higher in the first population as compared to the second. The latter observation might raise the question of the potential benefit of ECLS in such a severe population. It also highlights the need for better identification of patients who could benefit of such investment. Therefore, we have identified blood lactates level at ECLS implantation and reversible cause of OHCA as potential factors associated with better outcomes.

In the survivors of ECLS-treated PCAS population, the potential for recovery of neurological function was high (89% of surviving patients were alive without severe neurological impairment). These data are consistent with previously published data [5,7], although ECLS wasn't used in those latter studies. Faster time to implantation could be a particular endpoint to achieve, as suggested by available data in the setting of refractory cardiogenic shock [19]. Well-designed studies are lacking to support this hypothesis in the setting of PCAS. On the contrary, selecting patients the most likely to benefit for such a therapy could improve functional outcomes. Indeed, despite we observed that the mortality was not significantly different in the ECLS-treated population as compared to the control, blood lactate level, as well as the etiology of CA, was associated with neurological outcomes. Initiating ECLS on patients with low blood lactate level, and suffering for PCAS consecutive to reversible cause, could improve survival rates. Indeed, even though Bougouin et al. [9] showed no association between ECLS implantation and survival, our study suggests that the coronary etiology could

1 be a potential confounding factor. Reversible causes of myocardial dysfunction could then  
2 have a better prognosis in terms of myocardial recovery [20]. By contrast, in case of  
3 constituted myocardial infarct, the potential for recovery could be altered [21–23]. In fact,  
4 mortality observed in patients treated with ECLS for PCAS secondary to acute coronary  
5 syndrome, was higher than mortality observed in patients treated with ECLS for reversible  
6 causes. The mortality rates observed in our study remained high, but were comparable to  
7 those reported in the two previously published studies, respectively 72 [8] and 73% [9].

8 Complications occurred frequently, but were close to those reported in a meta-analysis of 20  
9 studies evaluating ECLS usage [24]. The most frequent complication in our study was acute  
10 kidney injury requesting renal replacement therapy (50%), being probably more a marker of  
11 the severity of the shock rather than a specific complication of ECLS. On the contrary, the  
12 high rates of specific complications of ECLS observed in our cohort, as the rate of lower limb  
13 ischemia (28% versus 17% in Cheng's study [24]), could worsened the prognosis of some  
14 patients. However, ECLS implantation was performed by physicians trained to percutaneous  
15 cannulation with previously published good results [11].

16 The retrospective design of the study limits the strength of the findings. We focused on a  
17 specific subpopulation of PCAS patients, and we retrieved data from 10 years' experience of  
18 two tertiary care centers. No randomized study could have been achievable in a reasonable  
19 time-frame. A matched analysis designed to identify the variables associated with survival  
20 would have been useful, but the low sample size of the ECLS cohort, as well as the particular  
21 severity of these patients have prevented us to conduct such a matching. Moreover, we were  
22 unable to collect information regarding severity at admission in the control population.

23 We limited the inclusion to the patients admitted for OHCA on purpose, even though the  
24 outcomes of the 3 patients non-included could have influenced the overall results of this  
25 study. Indeed, OHCA is a sudden and life-threatening pathology for whom the delay for  
26 initiation of the treatments is a key aspect of the prognosis. In-Hospital CA is a more

1 heterogeneous entity, where pre-existing life-threatening pathology leads to CA. The  
2 prognosis of the CA should be the combination of the pre-existing condition and the CA by  
3 itself. It would have been difficult to conclude on the ECLS intervention, because of this  
4 heterogeneity.

5

## 6 **Conclusion**

7 **Despite high rate of death in the ECLS-treated population, the neurological outcomes of the**  
8 **survivors suggest a potential beneficial effect of ECLS on neurological recovery and justify its**  
9 **implantation for extremely severe population, as a salvage therapy.** ~~While ECLS initiation,~~  
10 ~~reported in this present work, does not impact mortality, neurologic outcomes of survivors~~  
11 ~~suggest a potential beneficial effect on neurological recovery. The neurological evolution~~  
12 ~~could be more likely related to the initial brain injury, rather than the PCAS by itself.~~  
13 ~~Furthermore,~~ Reversible etiologies of cardiac arrest were associated with better outcomes,  
14 emphasizing on selection of patients who could benefit of such a therapy. Considering the  
15 assistance only for patients for whom the myocardial depression has the potential to recover  
16 could be an interesting option to improve outcomes. Then, considering ECLS for a carefully  
17 selected population of PCAS patients could be promising.

18

## 19 **Acknowledgment**

20 We would like to thank intensive care departments in Lariboisière and Cochin hospitals, for  
21 having helping us to gather data.

22

## 23 **References:**

24 [1] Atwood C, Eisenberg MS, Herlitz J, Rea TD. Incidence of EMS-treated out-of-hospital cardiac  
25 arrest in Europe. Resuscitation 2005;67:75–80. doi:10.1016/j.resuscitation.2005.03.021.

- 1 [2] Dumas F, White L, Stubbs BA, Cariou A, Rea TD. Long-Term Prognosis Following Resuscitation  
2 From Out of Hospital Cardiac Arrest. *J Am Coll Cardiol* 2012;60:21–7.  
3 doi:10.1016/j.jacc.2012.03.036.
- 4 [3] Laver S, Farrow C, Turner D, Nolan J. Mode of death after admission to an intensive care unit  
5 following cardiac arrest. *Intensive Care Med* 2004;30:2126–8. doi:10.1007/s00134-004-2425-z.
- 6 [4] Nolan JP, Laver SR, Welch CA, Harrison DA, Gupta V, Rowan K. Outcome following admission to  
7 UK intensive care units after cardiac arrest: a secondary analysis of the ICNARC Case Mix  
8 Programme Database\*: ICNARC Case Mix Programme Database. *Anaesthesia* 2007;62:1207–16.  
9 doi:10.1111/j.1365-2044.2007.05232.x.
- 10 [5] Lemiale V, Dumas F, Mongardon N, Giovanetti O, Charpentier J, Chiche J-D, et al. Intensive care  
11 unit mortality after cardiac arrest: the relative contribution of shock and brain injury in a large  
12 cohort. *Intensive Care Med* 2013;39:1972–80. doi:10.1007/s00134-013-3043-4.
- 13 [6] Mongardon N, Dumas F, Ricome S, Grimaldi D, Hissem T, Pène F, et al. Postcardiac arrest  
14 syndrome: from immediate resuscitation to long-term outcome. *Ann Intensive Care* 2011;1:45.
- 15 [7] Laurent I, Monchi M, Chiche J-D, Joly L-M, Spaulding C, énédicté Bourgeois B, et al. Reversible  
16 myocardial dysfunction in survivors of out-of-hospital cardiac arrest. *J Am Coll Cardiol*  
17 2002;40:2110–2116.
- 18 [8] de Chambrun MP, Bréchet N, Lebreton G, Schmidt M, Hekimian G, Demondion P, et al.  
19 Venoarterial extracorporeal membrane oxygenation for refractory cardiogenic shock post-  
20 cardiac arrest. *Intensive Care Med* 2016. doi:10.1007/s00134-016-4541-y.
- 21 [9] Bougouin W, Aissaoui N, Combes A, Deye N, Lamhaut L, Jost D, et al. Post-cardiac arrest shock  
22 treated with veno-arterial extracorporeal membrane oxygenation. *Resuscitation* 2017;110:126–  
23 32. doi:10.1016/j.resuscitation.2016.11.005.
- 24 [10] Chelly J, Mongardon N, Dumas F, Varenne O, Spaulding C, Vignaux O, et al. Benefit of an early  
25 and systematic imaging procedure after cardiac arrest: Insights from the PROCAT (Parisian  
26 Region Out of Hospital Cardiac Arrest) registry. *Resuscitation* 2012;83:1444–50.  
27 doi:10.1016/j.resuscitation.2012.08.321.
- 28 [11] Mégarbane B, Leprince P, Deye N, Résière D, Guerrier G, Rettab S, et al. Emergency feasibility in  
29 medical intensive care unit of extracorporeal life support for refractory cardiac arrest. *Intensive*  
30 *Care Med* 2007;33:758–64. doi:10.1007/s00134-007-0568-4.
- 31 [12] Extracorporeal Life Support Organization (ELSO). ELSO Guidelines for Adult Cardiac Failure v1.3  
32 2013. <https://www.else.org/resources/guidelines.aspx>.
- 33 [13] Morley PT, Atkins DL, Billi JE, Bossaert L, Callaway CW, de Caen AR, et al. Part 3: Evidence  
34 Evaluation Process: 2010 International Consensus on Cardiopulmonary Resuscitation and  
35 Emergency Cardiovascular Care Science With Treatment Recommendations. *Circulation*  
36 2010;122:S283–90. doi:10.1161/CIRCULATIONAHA.110.970947.
- 37 [14] Peberdy MA, Callaway CW, Neumar RW, Geocadin RG, Zimmerman JL, Donnino M, et al. Part 9:  
38 Post-Cardiac Arrest Care: 2010 American Heart Association Guidelines for Cardiopulmonary  
39 Resuscitation and Emergency Cardiovascular Care. *Circulation* 2010;122:S768–86.  
40 doi:10.1161/CIRCULATIONAHA.110.971002.
- 41 [15] Wijdicks EFM, Hijdra A, Young GB, Bassetti CL, Wiebe S. Practice Parameter: Prediction of  
42 outcome in comatose survivors after cardiopulmonary resuscitation (an evidence-based  
43 review): Report of the Quality Standards Subcommittee of the American Academy of  
44 Neurology. *Neurology* 2006;67:203–10. doi:10.1212/01.wnl.0000227183.21314.cd.
- 45 [16] Booth CM, Boone RH, Tomlinson G, Detsky AS. Is this patient dead, vegetative, or severely  
46 neurologically impaired?: assessing outcome for comatose survivors of cardiac arrest. *Jama*  
47 2004;291:870–879.
- 48 [17] Phelps R, Dumas F, Maynard C, Silver J, Rea T. Cerebral Performance Category and Long-Term  
49 Prognosis Following Out-of-Hospital Cardiac Arrest\*: *Crit Care Med* 2013;41:1252–7.  
50 doi:10.1097/CCM.0b013e31827ca975.
- 51 [18] Adrie C, Cariou A, Mourvillier B, Laurent I, Dabbane H, Hantala F, et al. Predicting survival with  
52 good neurological recovery at hospital admission after successful resuscitation of out-of-

- 1 hospital cardiac arrest: the OHCA score. *Eur Heart J* 2006;27:2840–5.  
2 doi:10.1093/eurheartj/ehl335.
- 3 [19] Rihal CS, Naidu SS, Givertz MM, Szeto WY, Burke JA, Kapur NK, et al. 2015 SCAI/ACC/HFSA/STS  
4 Clinical Expert Consensus Statement on the Use of Percutaneous Mechanical Circulatory  
5 Support Devices in Cardiovascular Care (Endorsed by the American Heart Association, the  
6 Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencion;  
7 Affirmation of Value by the Canadian Association of Interventional Cardiology–Association  
8 Canadienne de Cardiologie d’intervention)\*. *J Card Fail* 2015;21:499–518.  
9 doi:10.1016/j.cardfail.2015.03.002.
- 10 [20] Shavadia J, Zheng Y, Maleki ND, Huber K, Halvorsen S, Goldstein P, et al. Infarct Size, Shock, and  
11 Heart Failure: Does Reperfusion Strategy Matter in Early Presenting Patients With ST-Segment  
12 Elevation Myocardial Infarction? *J Am Heart Assoc* 2015;4:e002049.
- 13 [21] Sakamoto S, Taniguchi N, Nakajima S, Takahashi A. Extracorporeal Life Support for Cardiogenic  
14 Shock or Cardiac Arrest Due to Acute Coronary Syndrome. *Ann Thorac Surg* 2012;94:1–7.  
15 doi:10.1016/j.athoracsur.2012.01.032.
- 16 [22] Chen J-S, Ko W-J, Yu H-Y, Lai L-P, Huang S-C, Chi N-H, et al. Analysis of the outcome for patients  
17 experiencing myocardial infarction and cardiopulmonary resuscitation refractory to  
18 conventional therapies necessitating extracorporeal life support rescue\*: *Crit Care Med*  
19 2006;34:950–7. doi:10.1097/01.CCM.0000206103.35460.1F.
- 20 [23] Chen Y-S, Yu H-Y, Huang S-C, Chiu K-M, Lin T-Y, Lai L-P, et al. Experience and result of  
21 extracorporeal membrane oxygenation in treating fulminant myocarditis with shock: what  
22 mechanical support should be considered first? *J Heart Lung Transplant* 2005;24:81–87.
- 23 [24] Cheng R, Hachamovitch R, Kittleson M, Patel J, Arabia F, Moriguchi J, et al. Complications of  
24 Extracorporeal Membrane Oxygenation for Treatment of Cardiogenic Shock and Cardiac Arrest:  
25 A Meta-Analysis of 1,866 Adult Patients. *Ann Thorac Surg* 2014;97:610–6.  
26 doi:10.1016/j.athoracsur.2013.09.008.  
27

28

1 **TABLES**

2 **Table 1. General characteristics of the ECLS population according to outcome.** Results  
 3 are expressed as median [IQR] or n (%).

4

	All N = 43	Favorable Outcome N = 8	Poor Outcome N = 35	P Value
Age (yo)	54 [46 - 59]	43 [35 - 54]	55 [49 - 61]	0.029
Male n (%)	32 (74)	5 (62)	27 (77)	0.409
Body Mass Index	26 [25 - 28]	27 [25 - 31]	26 [25 - 28]	0.736
<b>Previous Medical Diseases</b>				
Coronaropathy n (%)	9 (21)	1 (12)	8 (23)	0.535
Diabetes mellitus n (%)	7 (16)	0 (0)	7 (20)	0.18
Hypertension n (%)	15 (35)	1 (12)	14 (40)	0.151
Dyslipidemia n (%)	6 (14)	1 (12)	5 (14)	0.917
Active smoker n (%)	4 (9)	0 (0)	4 (11)	0.336
<b>Severity scores on admission</b>				
IGS II	73 [67 - 81]	70 [66 - 79]	73 [68 - 82]	0.468
SOFA score	12 [11 - 15]	12 [10 - 12]	13 [12 - 15]	0.227
SOFA cardio-vascular	4 [4 - 4]	4 [4 - 4]	4 [4 - 4]	-
OHCA score	39 [31 - 51]	32 [26 - 36]	42 [33 - 52]	0.078
<b>Biological Data on admission</b>				
pH	7.19 [7.05 - 7.26]	7.15 [7.11 - 7.23]	7.19 [6.97 - 7.26]	0.521
Troponin (µmol/l)	5.5 [1.32 - 63.2]	7.2 [1.86 - 20.98]	4 [1.35 - 63.7]	0.984
Blood lactate (mmol/l)	10 [6 - 13]	6 [4 - 8]	11 [7 - 14]	0.029
Serum creatinine (µmol/l)	148 [138 - 188]	150 [134 - 164]	148 [138 - 198]	0.708
Serum potassium (mmol/l)	3.7 [3.2 - 4.2]	3.3 [2.9 - 4]	3.8 [3.4 - 4.4]	0.147
<b>Cardiac Arrest Characteristics</b>				
No Flow (min)	2 [0 - 10]	1 [0 - 9]	3 [0 - 10]	0.734
Low Flow (min)	28 [14 - 42]	25 [11 - 30]	28 [18 - 48]	0.28
Adrenaline bolus (mg)	3 [1 - 9]	1 [0 - 3]	4 [1 - 9]	0.168
Non public location n (%)	16 (37)	2 (25)	14 (40)	0.445
Bystander CPR n (%)	32 (74)	5 (62)	27 (77)	0.414
Shockable rhythm n (%)	26 (60)	4 (50)	22 (63)	0.519
Coronary Angiogram n (%)	38 (88)	7 (88)	31 (89)	0.37
Coronary Angioplasty n (%)	15 (35)	2 (25)	13 (37)	0.414
Hypothermia n (%)	33 (77)	6 (75)	27 (77)	0.207

**Cardiac Arrest Diagnoses**

Atrioventricular block <i>n (%)</i>	3 (7)	1 (12)	2 (6)	0.5
Coma <i>n (%)</i>	1 (2)	0 (0)	1 (3)	0.688
Hyperkalemia <i>n (%)</i>	2 (5)	0 (0)	2 (6)	0.534
Asphyxia <i>n (%)</i>	3 (7)	1 (12)	2 (6)	0.5
ACS <i>n (%)</i>	26 (60)	2 (25)	24 (69)	0.009
Tamponnade <i>n (%)</i>	1 (2)	0 (0)	1 (3)	0.688
Arrhythmia <i>n (%)</i>	6 (14)	3 (38)	3 (9)	0.03
Drowning <i>n (%)</i>	1 (2)	0 (0)	1 (3)	0.688

**Assistances**

Impella <i>n (%)</i>	7 (16)	1 (12)	6 (17)	0.77
IACPБ <i>n (%)</i>	8 (19)	3 (38)	5 (14)	0.139

- 1 BMI: Body Mass Index ; CA : Cardiac Arrest ; CPR : Cardio-Pulmonary Resuscitation; IACPБ : Intra-
- 2 Aortic Counter-Pulsation Balloon; OHCA : Out-Of-Hospital Cardiac Arrest ; SOFA : Sequential Organ
- 3 Failure Assessment ; ACS : Acute Coronary Syndrome

4

5

6

1 **Table 2. Hemodynamic parameters and ECLS complications in the ECLS population**  
 2 **according to outcome.** Results are expressed as median [IQR] or n (%).

	All N = 43	Favorable Outcome N = 8	Poor Outcome N = 35	P Value
<b><i>ECLS Implantation Data</i></b>				
CA to ECLS delay ( <i>hours</i> )	9 [6 - 16]	8 [7 - 18]	10 [6 - 15]	0.967
Hemodynamic				
MAP ( <i>mmHg</i> )	58 [44 - 72]	60 [55 - 74]	57 [42 - 68]	0.553
Cardiac Index ( <i>L/min/m<sup>2</sup></i> )	1,37 [0,9 - 1,81]	1.73 [1.08 - 2.05]	1.36 [0.94 - 1.39]	0.786
Cardiac Power ( <i>Watt</i> )	0,27 [0,14 - 0,44]	0.38 [0.25 - 0.49]	0.18 [0.14 - 0.35]	1
LVEF (%)	15 [10 - 25]	15 [12 - 21]	20 [10 - 25]	0.597
Inotropic Equivalent	220 [137 - 410]	160 [118 - 193]	230 [140 - 410]	0.247
<b><i>ECLS Efficacy</i></b>				
ECLS Withdrawal <i>n (%)</i>	8 (19)	7 (88)	1 (3)	< 0.001
Inefficacy <i>n (%)</i>	11 (26)	0 (0)	11 (31)	0.092
CPC ≤ 2 at D90 <i>n (%)</i>	8 (19)	7 (88)	1 (3)	< 0.001
Death at 1 year <i>n (%)</i>	35 (81)	0 (0)	35 (100)	< 0.001
<b><i>Potential complications ECLS-related</i></b>				
Complications	36 (84)	6 (75)	30 (86)	0.554
Total per patient (n = 71)	2 [1 - 3]	1 [1 - 2]	2 [1 - 2]	0.743
Hemorrhage <i>n (%)</i>	10 (23)	0 (0)	10 (29)	-
Lower Limb Ischemia <i>n (%)</i>	12 (28)	3 (38)	9 (26)	-
Coagulopathy <i>n (%)</i>	12 (28)	0 (0)	12 (34)	-
Hemolysis <i>n (%)</i>	1 (0)	0 (0)	1 (3)	-
ARDS <i>n (%)</i>	1 (0)	0 (0)	1 (3)	-
Femoral site infection <i>n (%)</i>	2 (0)	2 (25)	0 (0)	-
Renal Replacement Therapy <i>n (%)</i>	21 (50)	5 (63)	16 (46)	-
VAP <i>n (%)</i>	4 (1)	0 (0)	4 (11)	-
GastroIntestinal Bleeding <i>n (%)</i>	1 (0)	0 (0)	1 (3)	-
Mesenteric Ischemia <i>n (%)</i>	7 (16)	1 (13)	6 (17)	-

3 CA: Cardiac Arrest; LVEF: Left Ventricle Ejection Fraction; CPC : Cerebral Performance Category  
 4 Score ; ARDS : Acute Respiratory Distress Syndrome ; VAP : Ventilator Associated Pneumonia

5

6



1 **Table 3. Comparison between ECLS treated PCAS patients (ECLS group) and non**  
 2 **ECLS treated PCAS patients group (Control group). Results are expressed as median**  
 3 **[IQR] or n (%).**

	<b>Overall n = 921</b>	<b>ECLS group n = 43</b>	<b>Control Group n = 878</b>	<b>P Value</b>
Age (yo)	62 [52 - 74]	54 [46 - 59]	63 [52 - 74]	<0.001
Male n (%)	633 (69)	32 (74)	601 (68)	0.50
Body Mass Index	25 [23 - 28]	26 [25 - 28]	25 [23 - 28]	0.19
<b>Previous Medical History</b>				
Coronaropathy n (%)	205 (24)	9 (21)	196 (25)	0.72
Diabete mellitus n (%)	184 (22)	7 (16)	177 (23)	0.45
Arterial Hypertension n (%)	374 (45)	15 (35)	359 (46)	0.21
Dyslipidemia n (%)	210 (26)	6 (14)	204 (26)	0.08
Active smoker n (%)	295 (40)	4 (9)	291 (42)	<0.001
<b>Biological parameters on admission</b>				
Blood Lactate (mmol/l)	5 [3 - 10]	10 [6 - 13]	5 [3 - 10]	0.002
Serum Creatinine (µmol/l)	109 [84 - 146]	148 [138 - 188]	108 [83 - 144]	<0.001
Potassium (mmol/l)	3.9 [3.3 - 4.5]	3.7 [3.2 - 4.2]	3.9 [3.3 - 4.5]	0.66
<b>Characteristics of Cardiac Arrest</b>				
No Flow (min)	3 [0 - 8]	2 [0 - 10]	3 [0 - 8]	0.33
Low Flow (min)	16 [10 - 25]	28 [14 - 42]	16 [10 - 25]	0.001
Adrenaline bolus (mg)	2 [0 - 5]	3 [1 - 9]	2 [0 - 5]	0.41
Non public location n (%)	617 (67)	16 (37)	601 (69)	<0.001
Bystander CPR n (%)	482 (52)	32 (74)	450 (51)	0.007
Shockable initial rythm n (%)	439 (48)	26 (60)	413 (47)	0.09
Coronary Angiogram n (%)	622 (68)	38 (90)	584 (67)	0.001
Coronary Angioplasty n (%)	238 (27)	15 (35)	223 (25)	0.14
Hypothermia n (%)	755 (80)	33 (77)	722 (82)	0.83

4 CPR : Cardio-Pulmonary Resuscitation;

5

6

7

8

1 **Table 4. Factors associated with survival at ICU discharge in the whole PCAS**  
 2 **population (n=921).** Results are expressed as median [IQR] or n (%)

	Survivors n = 237	Death n = 684	P Value
Age (yo)	61 [49 - 71]	63 [53 - 75]	0.01
Male n (%)	165 (70)	468 (68)	0.73
Body Mass Index	26 [22 - 28]	25 [23 - 30]	0.22
<b>Previous Medical Diseases</b>			
Coronaropathy n (%)	13 (6)	27 (4)	0.35
Diabetes mellitus n (%)	28 (13)	156 (26)	<0.001
Hypertension n (%)	91 (41)	283 (47)	0.18
Dyslipidemia n (%)	66 (30)	144 (24)	0.11
Active smoker n (%)	84 (40)	211 (40)	0.91
<b>Biological Data at admission</b>			
Blood lactate (mmol/l)	3 [2 - 5]	9 [5 - 13]	<0.001
Serum creatinine (µmol/l)	98 [76 - 124]	129 [97 - 169]	<0.001
Serum potassium (mmol/l)	3.6 [3.1 - 4.2]	4 [3.4 - 4.8]	<0.001
<b>Cardiac Arrest Characteristics</b>			
No Flow (min)	2 [0 - 5]	5 [0 - 10]	<0.001
Low Flow (min)	13 [7 - 20]	20 [13 - 30]	<0.001
Adrenaline (mg)	0 [0 - 3]	3 [2 - 6]	<0.001
Non public location n (%)	110 (47)	188 (28)	<0.001
Bystander CPR n (%)	140 (61)	342 (51)	0.008
Shockable rhythm n (%)	163 (69)	276 (40)	<0.001
Coronary Angiogram n (%)	187 (79)	435 (64)	<0.001
Coronary Angioplasty n (%)	85 (39)	153 (24)	<0.001
Hypothermia n (%)	216 (92)	539 (79)	<0.001
<b>Assistances</b>			
ECMO n (%)	9 (4)	34 (5)	0.59

3

4

5

1 **FIGURE LEGENDS**

2

3 **Figure 1: Mode and timing of death during ICU length of stay in the ECLS treated**  
4 **population.**

5

6 **Figure 2: Multivariate analysis of factors associated with ECLS initiation in the PCAS**  
7 **population**

8

9 **Figure S1: Serum Lactate levels according to neurological outcomes**

10

11

12